Skip to main content
Lab Grimoire
TW EN
Coffee
Health Evidence

The Fasting Trial's 41 and 50: Lipid Signals Are Not Cardiovascular Proof

A six-month intermittent-fasting report describes lipid changes but gives conflicting participant counts in its abstract and main text. We separate the study design, pooled analysis, energy restriction, and clinical endpoints to show what the findings can and cannot support.

Author
CY
Published
Updated
The Fasting Trial's 41 and 50: Lipid Signals Are Not Cardiovascular Proof

The pooled intermittent-fasting analysis reported a 23.4% decrease in triglycerides, yet the paper's abstract says 41 participants were randomized while its Methods and Results say 50. How should we read that percentage without turning a lipid marker into proof of fewer heart attacks? Start by reconciling the denominator, comparison, and endpoint.[1][2]

The study enrolled adults aged 30-65 years with overweight (BMI 24.8-35). Depending on BMI, participants fasted on two or three nonconsecutive days each week; on fasting days, they ate non-starchy vegetables with dressing, for less than 500 kcal. Participants self-reported an average 22.8% reduction in weekly energy intake, so the observed changes cannot be assigned to meal timing alone.[1]

First, the denominator: 41 and 50 remain inconsistent

The abstract reports 41 randomized; the Methods and Results report 50 randomized, and the trial registry lists an enrollment of 50.[1][2]

The article also says 49 participants began the intervention. The public text does not explain the discrepancy, so 41 should not be relabeled as the number of completers. During the first six months, Group A received intermittent fasting and Group B continued its habitual diet; 21 and 20 participants, respectively, completed that phase. Then 18 Group A completers continued fasting, while 19 Group B completers crossed over into fasting as Group D. The paper pooled the two fasting-exposure periods, A and D. That is like combining two ledger columns: it is not the original concurrent randomized comparison.[1]

Why not read the pooled percentages as a fasting-versus-control difference? Because Group D consists of control participants who crossed over after the first phase; after pooling, the comparison no longer preserves the original parallel randomized arms.

Study flow: enrollment discrepancy, initial randomized arms and crossover extension

Figure 1. Participant counts and crossover timeline. Arrows show study sequence, not biological causation.[1][2]

Fasting lipid study at a glance: participant counts, intervention, lipid signals and evidence limits

The intervention changed more than meal timing

The protocol also imposed weekly energy restriction, with two or three fasting days according to BMI. The lipid changes therefore cannot be attributed to the clock alone.[1]

Fasting days provided less than 500 kcal, and participants received monthly dietitian visits plus weekly phone follow-up. The reported 22.8% reduction in energy intake was self-reported. Energy restriction and weight change remain plausible alternative explanations, not factors this report ruled out.[1]

Lipid signals did not move every other marker

In the IF-combined A+D analysis, non-HDL-C was 11% below baseline (P < 0.001), and triglycerides decreased 23.4% (P < 0.007). These are results from pooled fasting exposure, not a single difference between two concurrent randomized groups.[1]

HDL-C increased but not significantly. At six months, the report also found no significant changes in blood pressure, fasting glucose, HOMA-IR, inflammatory markers, or carotid intima-media thickness.[1]

Lipid signals and evidence boundaries in the pooled intermittent-fasting analysis

Figure 2. Values are attributed to pooled A+D; changes in risk markers do not establish event prevention.[1]

Narrow the mechanistic and clinical conclusions

This report describes cardiovascular risk markers; it does not show that fasting prevents heart attacks or strokes. The paper presents exploratory metabolomic and transcriptomic analyses, and the authors did not directly analyze the gut microbiota.[1]

The reported association between non-HDL-C and a B-cell/IgA phenotype may suggest a shared mechanism, but it does not show that microbiota changes caused the lipid response. The study applies to adults aged 30-65 years with overweight, and its small sample and descriptive analyses limit generalizability. For readers, these findings are a signal for further testing, not an individual prescription or a substitute for medical care.[1]

Sources

[1] Barve et al., Nature Communications (2025)
[2] ClinicalTrials.gov: NCT01964118

Knowledge Context

References

  1. Barve et al. — Nature Communications — 2025

Frequently Asked Questions

Why does the abstract say 41 participants, while the main text and registry say 50?

The abstract reports 41 randomized participants. The Methods and Results report 50 randomized and 49 who began the intervention; ClinicalTrials.gov lists an enrollment of 50. The public text does not explain the discrepancy, so 41 should not be reinterpreted as the number of completers.[1][2]

Are the 11% non-HDL-C and 23.4% triglyceride changes fasting-versus-control differences?

No. Both values come from the pooled IF-combined A+D fasting-exposure analysis. Group D consisted of participants from the original control group who crossed over to fasting. These values are not a single concurrent randomized-arm contrast and should not be described as an effect size versus control.[1]

Does this study show that intermittent fasting prevents heart attacks or strokes?

No. The report describes lipid and other risk markers; it does not establish fewer cardiovascular events. The sample was small and the analyses exploratory, so biomarker changes should not be equated with event prevention.[1]

Were the lipid changes caused by changes in gut bacteria?

That is not established. The researchers did not directly analyze the gut microbiota. The reported association between non-HDL-C and a B-cell/IgA phenotype suggests a hypothesis, not a causal mechanism.[1] ## Sources [1] [Barve et al., *Nature Communications* (2025)](https://doi.org/10.1038/s41467-025-66366-8) [2] [ClinicalTrials.gov: NCT01964118](https://clinicaltrials.gov/study/NCT01964118)

Found this useful? RSS · X · Buy me a coffee